Subsequent Event

6 Months Ended

Jun. 30, 2013

Subsequent Events [Abstract]

Subsequent Events [Text Block]

Note 9—Subsequent Event

In July 2013, a newly-formed, wholly-owned subsidiary of the Company has entered into a Technology License Agreement (TLA) with a privately-held company. The TLA provides the Company the exclusive license for certain intellectual property related to the nutritional ingredient lunasin and other soy-related peptides and proteins. In consideration, the Company will pay the licensor $2 million; $1.15 million paid at closing, with the remaining obligation paid over the next four years in a series of annual payments ranging from $150,000 to $250,000. Subject to certain minimum and maximum volume thresholds, the Company will also pay the licensor royalties of 5% of sales during the first five years of the TLA and royalties ranging from 1% to 3% of sales during the remaining life of the TLA. The transaction was closed on July 23, 2013, and was primarily funded by a borrowing of $1.1 million from the company’s revolving loan agreement. The Company anticipates accounting for the TLA as a long-term finite-lived asset to be amortized over the life of the agreement.